Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Thymus Neoplasms × Everolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Breast Neoplasms 87 Carcinoma, Renal Cell 63 Neoplasm Metastasis 38 Neoplasms 32 Neuroendocrine Tumors 31 Kidney Neoplasms 24 Recurrence 16 Carcinoma, Non-Small-Cell Lung 16 Tuberous Sclerosis 14 Prostatic Neoplasms 14 Triple Negative Breast Neoplasms 13 Head and Neck Neoplasms 12 Glioblastoma 12 Carcinoma, Hepatocellular 12 Pancreatic Neoplasms 11 Lymphoma, Mantle-Cell 11 Lymphoma 11 Brain Neoplasms 11 Lymphoma, Large B-Cell, Diffuse 10 Leukemia, Lymphocytic, Chronic, B-Cell 10 Hodgkin Disease 10 Colorectal Neoplasms 10 Carcinoma, Neuroendocrine 10 Sarcoma 9 Precursor Cell Lymphoblastic Leukemia-Lymphoma 9 Glioma 9 Waldenstrom Macroglobulinemia 8 Lymphoma, Follicular 8 Lung Neoplasms 8 Carcinoid Tumor 8

Interventions

pembrolizumab 3 Drug Therapy 2 ribociclib 1 palbociclib 1 fludarabine 1 epacadostat 1 bosutinib 1 amrubicin 1 Sunitinib 1 Radiosurgery 1 Proton Therapy 1 Plicamycin 1 Pemetrexed 1 Magnetic Resonance Spectroscopy 1 Immunotherapy 1 Fluorodeoxyglucose F18 1 FAPI-46 1 Everolimus 1 Erlotinib Hydrochloride 1 Cyclophosphamide 1 Cisplatin 1 Blood Specimen Collection 1 Bevacizumab 1 177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05918302 2026-03-06

LEVEL

Grupo Espanol de Tumores Neuroendocrinos

Phase 3 Recruiting

Thymus Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡